Angiogenex Inc (AGGX) financial statements (2020 and earlier)

Company profile

Business Address 425 MADISON AVENUE, SUITE 902
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20494
Cash and cash equivalents20494
Prepaid expense3322
Total current assets:53515
Noncurrent Assets
TOTAL ASSETS:53515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:320384
Accrued liabilities180 
Employee-related liabilities95 
Interest and dividends payable4551
Other undisclosed accounts payable and accrued liabilities 333
Debt129139
Due to related parties160 
Other undisclosed current liabilities488620
Total current liabilities:1,0961,142
Noncurrent Liabilities
Liabilities, other than long-term debt2727
Due to related parties2727
Total noncurrent liabilities:2727
Total liabilities:1,1241,170
Stockholders' equity
Stockholders' equity attributable to parent(1,071)(655)
Common stock2929
Additional paid in capital5,9125,892
Accumulated deficit(7,012)(6,576)
Total stockholders' equity:(1,071)(655)
TOTAL LIABILITIES AND EQUITY:53515

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
Operating expenses(438)(646)
Other operating income (expense), net
(Other Expenses)
(9)37
Other undisclosed operating loss (37)
Operating loss:(447)(646)
Interest and debt expense1036
Loss from continuing operations before income taxes:(437)(610)
Income tax expense(11) 
Net loss:(448)(610)
Other undisclosed net income (loss) attributable to parent12(73)
Net loss available to common stockholders, diluted:(435)(683)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
Net loss:(448)(610)
Comprehensive loss, net of tax, attributable to parent:(448)(610)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: